For years, one question has hung over the conversation about NAD+ precursors and brain health: can oral NMN actually make it past the blood-brain barrier to raise NAD+ levels where it might matter most? The skepticism isn't unfounded. The blood-brain barrier is notoriously selective, a tight layer of cells that shields the central nervous system from many substances in the bloodstream. If a supplement can't cross, the thinking goes, then any cognitive or neuroprotective benefit is just wishful biochemistry.
A new study—the Berven 2026 investigation—set out to test that very assumption. It didn't settle every debate, but it did put a well-designed time course in the spotlight, one that directly measured how the brain responds to a high oral dose of NMN. The implications could shift how we think about supplement routines for cognitive aging, even if the results demand careful reading.
The Blood-Brain Barrier Myth: Why Doubt Oral NMN?
The doubt starts with a simple anatomy lesson. Endothelial cells lining the brain's capillaries are stitched together by tight junctions far more formidable than those elsewhere in the body. They keep pathogens and large molecules out, but they also ferry nutrients in through specialized transporters. The trouble with NMN is that its molecular size and charge led many researchers to assume passive diffusion wasn't going to happen—and that no specific transporter existed to carry it across.
That assumption matters for anyone watching the NAD+ space with an eye on brain fog, memory, or long-term cognitive resilience. After all, NAD+ declines with age, and that drop hits tissues differently. If oral NMN can't reach the brain, then the entire value proposition for mental clarity or neuronal repair gets stripped down to peripheral effects—valuable, but incomplete. The myth, then, isn't a myth in the sense of folklore; it's a physiological barrier that became a kind of default caution among scientists.
NMN Absorption and NAD+: What We Already Know
Before questioning brain uptake, the broader story of oral NMN had already moved from speculation to a solid body of human evidence. Studies show that swallowing NMN reliably bumps up blood NAD+ levels, and a dosage of up to 1,200 mg per day has been examined with no serious adverse effects turning up in the data. That safety finding alone opened the door for the kind of higher-dose brain study that later emerged.
Separately, researchers have connected NAD+ availability to two processes that underpin cellular health: sirtuin activation and mitochondrial function. According to a Fortune analysis of NAD+ supplements, the science points toward NAD+ playing a role in helping sirtuins do their job—proteins that influence DNA repair and metabolic regulation—and supporting the mitochondria that power our cells. Those connections have made NAD+ precursors popular well before brain-specific data came in.
But here's the gap that kept the blood-brain question alive. Most earlier trials didn't sample cerebrospinal fluid or use neuroimaging to track brain NAD+ metabolism. They measured blood, and blood alone. And while NR and NMN are the two most studied precursors, their pathways into cells differ. So an NMN result in plasma didn't automatically translate to neuronal tissue. That ambiguity left even informed consumers in a tough spot: confident in a whole-body NAD+ lift, uncertain about the brain.
Inside the Berven 2026 Study: 1,200 mg of Oral NMN
The Berven 2026 study didn't aim to be just another NAD+ precursor trial. Its design fixed a lens directly on the blood-brain barrier puzzle by administering 1,200 mg of oral NMN and then tracking brain NAD+ levels over a two-week time course. That focus—duration and target tissue together—was what made it one of the first investigations of its kind.
The protocol itself was straightforward: participants took a daily oral dose, and researchers collected data at multiple points to see if and when brain NAD+ concentrations changed. By using a time course rather than a single endpoint measurement, the study could potentially reveal not just whether NMN reached the brain, but the kinetics of that process. That detail matters because if a precursor does cross, the speed and sustainability of the rise might affect how people time their supplement intake.
It's worth noting that the study did not compare NMN to other precursors like NR. Its scope was narrower—answering, with direct evidence, whether the "oral NMN can't reach the brain" assumption held up under rigorous measurement. Whatever the findings, the mere attempt to collect that data signaled a turning point in how researchers think about NAD+ and the central nervous system.
What This Means for Your Supplement Routine
If the Berven 2026 study hints that oral NMN can indeed influence brain NAD+, then supplement users focused on cognitive health gain a new reason to look beyond blood-level data. It would suggest that a single precursor could potentially support both peripheral and central NAD+ pools, simplifying a stack that might otherwise require multiple compounds. Still, that's a big "if"—and until the results are fully interpreted, the practical takeaway is to stay open-minded about different delivery forms.
For some people, the most relevant shift isn't about NMN at all. It's about the possibility of using a direct NAD+ supplement that includes brain-specific nutrients. When you swallow NAD+ itself, the body must break it down and reassemble it, but pairing it with compounds that support neuronal function might create a different kind of support—one that doesn't rely on crossing the blood-brain barrier in its original form.
A Direct NAD+ Supplement with Brain Nutrients
One Brain Health Supplement takes that approach by combining NAD+ with alpha-glycerophosphocholine (Alpha-GPC), vitamin B12, and folate. Alpha-GPC is a source of choline, a nutrient the brain uses to build acetylcholine, a neurotransmitter tied to memory and attention. Meanwhile, B12 and folate are already recognized players in maintaining healthy nerve cells and supporting the biochemical pathways that keep homocysteine in check.
The formula doesn't claim to be a replacement for NMN or NR; it's a different tool. For someone who prefers a direct NAD+ product with a choline backbone and B-vitamin coverage, it's an option that mirrors the kind of multi-ingredient thinking common in brain-health stacks. The missing piece, of course, is whether any direct NAD+ supplement can outcompete precursor-driven NAD+ synthesis in neurons. That question remains open, and the Berven study doesn't answer it.
How to Choose a High-Quality NAD+ Supplement
Whether you lean toward a precursor or a direct NAD+ formula, the manufacturing standards behind the product matter as much as the ingredient list. Look for supplements made in a GMP-certified facility and ones backed by third-party testing from organizations like cGMP, NSF, SuppCo, Alkemist Assured, GRSA, or QPS. These certifications reduce the risk that what's on the label isn't what's in the bottle—a non-negotiable starting point for a compound as delicate as NAD+.
Cost per serving can also work as a rough quality signal, not because expensive equals better, but because the numbers clarify what you're paying for. In a Fortune overview of NAD+ supplements, daily serving estimates came in at $1.83 for Tru Niagen and $1.73 for Wonderfeel, with Omre at $2.00. Those figures don't tell you which supplement is more effective, but they do let you weigh the budget against factors like additional ingredients or the existence of extensive peer-reviewed research—Tru Niagen's Niagen, for example, has been the subject of more than 45 peer-reviewed clinical studies. If a product includes a bioavailability enhancer like BioPerine, that's another line on the balance sheet: a small addition that may influence how much of the active actually gets into circulation.
Transparency about ingredient sourcing rounds out the picture. A company that publishes third-party lab results and discloses where its raw materials come from tends to inspire more confidence than one that guards those details. In a category still short on long-term brain-specific data, that clarity is at least something you can verify today.